Further, infusion of autologous T-lymphocytes, engineered to express a chimeric antigen receptor (CAR) for the CD19 B-cell antigen, can induce remissions in patients with advanced lymphoblastic leukemia and lymphoma (reviewed in [2]). Here, CD19 is linked to lymphoma.